Clinical study on Tolerability, pharmacodynamics and pharmacokinetics of multiple doses of Albuvirtide injection in HIV-infected patients

Trial Profile

Clinical study on Tolerability, pharmacodynamics and pharmacokinetics of multiple doses of Albuvirtide injection in HIV-infected patients

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Albuvirtide (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 21 May 2012 Actual end date changed from 1 Jun 2011 to 31 Aug 20111 as reported by Chinese Clinical Trial Register.
    • 19 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top